Sodium oxybate controlled release - Avadel Pharmaceuticals

Drug Profile

Sodium oxybate controlled release - Avadel Pharmaceuticals

Alternative Names: FT 218; Micropump® sodium oxybate

Latest Information Update: 11 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Flamel Technologies
  • Developer Avadel Pharmaceuticals
  • Class Butyric acids; Hydroxybutyrates; Sleep disorder therapies; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy
  • New Molecular Entity No

Highest Development Phases

  • Phase III Narcolepsy

Most Recent Events

  • 10 Jan 2018 Sodium oxybate controlled release receives Orphan Drug status for Narcolepsy in USA
  • 29 Dec 2017 Avadel Pharmaceuticals plans to submit an NDA with the US FDA in 2018
  • 30 Oct 2017 Avadel Pharmaceuticals initiates enrolment in a phase III trial for Narcolepsy (In volunteers) in Netherlands (EudraCT2016-004342-28)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top